Zentalis Pharmaceuticals, Inc. (ZNTL)
NasdaqGM · USD · Healthcare · Biotechnology
$2.07 (-6.33%) as of
Key statistics
- Market cap
- 203.11M
- Forward P/E
- -1.17
- EPS (TTM)
- -1.9600
- Dividend yield
- 0.00%
- 52-week range
- 1.2120 – 6.9500
- Beta
- 1.94
- Profit margin
- 0.00%
- Analyst target
- $7.44
- Volume
- 1.04M
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA, United States
- Employees
- 106
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.